Réactifs et instruments pour l'immunologie, la biologie cellulaire et la biologie moléculaire.

BMS-309403 [300657-03-8]

Imprimer

Référence NB-64-28790-1mL

Conditionnement : 1mLx10mM(inDMSO)

Marque : Neo Biotech

Demander plus d'informations

Remove All

BMS-309403

Copy Product Info

Synonyms:

Catalog No. T4534 Copy Product Info

Purity: 99.98%

BMS309403 is a potent and selective inhibitor of adipocyte fatty acid binding protein aFABP. It improves endothelial function in apolipoprotein E-deficient mice and cultured human endothelial cells. It interacts with the fatty acid binding pocket inside the protein and competitively inhibits the binding of endogenous fatty acids.

Cas No. 300657-03-8

For research use only—not for human use. No sales to individuals. Use as intended only.

Select Batch

Purity:99.98%

Color:White to Yellow

Product Introduction

Bioactivity

Description	BMS309403 is a potent and selective inhibitor of adipocyte fatty acid binding protein aFABP. It improves endothelial function in apolipoprotein E-deficient mice and cultured human endothelial cells. It interacts with the fatty acid binding pocket inside the protein and competitively inhibits the binding of endogenous fatty acids.
Targets & IC50	FABP4:< 2 nM, FABP3: 250 nM , FABP5: 350 nM
In vitro	Treatment with BMS309403 significantly reduced MCP-1 production in THP-1 macrophages in a dose- and time-dependent manner.[1]
In vivo	METHODS: 3 weeks after the onset of diabetes, mice were orally treated with BMS309403 (40 mg/kg, daily) for 3 weeks. During treatment, monitor blood sugar levels. RESULTS BMS309403 can significantly reduce the protein expression of FABP4 in mouse retinal tissue and partially reduce blood glucose levels in mice. [2]

Chemical Properties

Molecular Weight	474.55
Formula	C₃₁H₂₆N₂O₃
Cas No.	300657-03-8
Smiles	CCc1c(c(nn1-c1ccccc1-c1cccc(OCC(O)=O)c1)-c1ccccc1)-c1ccccc1
Relative Density.	1.17 g/cm3

Storage & Solubility Information

Storage

Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

Ethanol: 20 mM, Heating is recommended.

DMSO: 255 mg/mL (537.35 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.21 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

Ethanol/DMSO

	1mg	5mg	10mg	50mg
1 mM	2.1073 mL	10.5363 mL	21.0726 mL	105.3630 mL
5 mM	0.4215 mL	2.1073 mL	4.2145 mL	21.0726 mL
10 mM	0.2107 mL	1.0536 mL	2.1073 mL	10.5363 mL
20 mM	0.1054 mL	0.5268 mL	1.0536 mL	5.2681 mL

DMSO

	1mg	5mg	10mg	50mg
50 mM	0.0421 mL	0.2107 mL	0.4215 mL	2.1073 mL
100 mM	0.0211 mL	0.1054 mL	0.2107 mL	1.0536 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 µL Tween 80 and mix well until fully clarified.

3) Add 450 µL Saline,PBS or ddH₂O and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

Keywords

uptakeselectiveoralInhibitorinhibitglucosefunctionFatty acid-binding proteinFABP5FABP4FABP3FABPendothelialBMS-309403BMS309403BMS 309403

Related Tags: BMS-309403 chemical structure | BMS-309403 in vivo | BMS-309403 in vitro | BMS-309403 formula | BMS-309403 molecular weight